<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512170</url>
  </required_header>
  <id_info>
    <org_study_id>HEC585-P-02 / CRC-C1938</org_study_id>
    <nct_id>NCT04512170</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Single and Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Randomized, Open-label，Crossover, Food Effect Study of HEC585 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC585 in Healthy Male and&#xD;
      Female Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">June 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Ascending Single and Multiple Dose Study is Double-blind design; Food Effect Study is open-label design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of HEC585 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose and Multiple Ascending Doses</measure>
    <time_frame>up to 18 days</time_frame>
    <description>To investigate the safety and tolerability of HEC585 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD and MAD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters - AUC0-∞</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>area under the concentration versus time curve (AUC) from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - Cmax</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Geometric Mean of Maximum Observed Plasma Concentration of HEC585</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -tmax</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -t½</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>apparent terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -Vz/F</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - MRT</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>the Mean Residence Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -CL/F</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>the Apparent Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -R</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>the Accumulation Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Effect of Food on PK parameters of HEC585</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>A single dose HEC585（pilot trial arm）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive a single dose of HEC585</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 1）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive Single and multiple doses of HEC585 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 2）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive Single and multiple doses of HEC585 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 3）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive Single and multiple doses of HEC585 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HEC585 （Part 2，Fed/Fasting）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>two-period study at 400 mg dose group (part 3，Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive Single/multiple doses of HEC585 or matching placebo in two cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC585</intervention_name>
    <description>single or Mulltiple doses up to 10 days</description>
    <arm_group_label>A single dose HEC585（pilot trial arm）</arm_group_label>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 1）</arm_group_label>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 2）</arm_group_label>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 3）</arm_group_label>
    <arm_group_label>Single dose of HEC585 （Part 2，Fed/Fasting）</arm_group_label>
    <arm_group_label>two-period study at 400 mg dose group (part 3，Fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single or Mulltiple doses up to 10 days</description>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 1）</arm_group_label>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 2）</arm_group_label>
    <arm_group_label>Single and Mulltiple doses HEC585（ Part 1, Cohort 3）</arm_group_label>
    <arm_group_label>Single dose of HEC585 （Part 2，Fed/Fasting）</arm_group_label>
    <arm_group_label>two-period study at 400 mg dose group (part 3，Fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are willing and are able to provide a written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout&#xD;
             the trial.&#xD;
&#xD;
          3. Subjects aged between 18 and 45 (both inclusive) years old.&#xD;
&#xD;
          4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body&#xD;
             mass index ≥19 and ≤28 kg/m2 at screening.&#xD;
&#xD;
          5. Subjects, who are healthy, as having no clinically significant abnormalities in vital&#xD;
             signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP&#xD;
             antibodies at screening.&#xD;
&#xD;
          2. Subjects suffering from gastrointestinal diseases that can interfere with absorption&#xD;
             or metabolism of drugs within 6 months before screening; and/or with history of&#xD;
             central nervous system, cardiovascular system, digestive system, respiratory system,&#xD;
             urinary system, blood system, immune system (such as thymus disease), reproductive&#xD;
             system (such as prostate, testis, epididymis, ovarian disease); and/or thyroid disease&#xD;
             or previous thyroid surgery, malignant tumor, metabolic disorder or others medical&#xD;
             conditions (such as history of mental illness, etc.) that are not suitable for&#xD;
             clinical trial participation.&#xD;
&#xD;
          3. Known allergic reactions or hypersensitivity to any excipient of the drug&#xD;
             formulation(s)， anaphylaxis physique.&#xD;
&#xD;
          4. Use of any prescription or non-prescription medications within 14 days prior to&#xD;
             initial dosing，Use of any medications known to inhibit or induce cytochrome P enzyme&#xD;
             drug metabolism within 28 days prior to initial dosing.&#xD;
&#xD;
          5. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit&#xD;
             within 48 hours prior to initial dosing.&#xD;
&#xD;
          6. Positive results from urine drug screen test.&#xD;
&#xD;
          7. History of alcoholism or drink regularly within 3 months prior to the study(defined as&#xD;
             Alcohol consumption of &gt; 21 units/week), or positive results from alcohol breath test.&#xD;
&#xD;
          8. Regular smoking of more than 10 cigarettes per day within 3 months before&#xD;
             administration of study drug, or inability to refrain from smoking during the course&#xD;
             of the study.&#xD;
&#xD;
          9. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.&#xD;
&#xD;
         10. Subjects who plan to receive or have had organ transplants.&#xD;
&#xD;
         11. Females who are lactating/breastfeeding, or positive result from pregnancy test for&#xD;
             women of child-bearing potential.&#xD;
&#xD;
         12. Subjects who participated in another clinical trial within 3 months prior to initial&#xD;
             dosing.&#xD;
&#xD;
         13. Any other condition with in the opinion of the investigator would render the patient&#xD;
             unsuitable for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YanMei Liu, MS</last_name>
    <phone>021-54030254</phone>
    <email>ymliu@shxh-centerlab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YanMei Liu, MS</last_name>
      <phone>021-54030254</phone>
      <email>ymliu@shxh-centerlab.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

